Sun Pharmaceutical Industries Limited , India's largest pharmaceutical company, has reported robust financial results for the first quarter, despite facing headwinds from US President Donald Trump's demands for lower drug prices. The company's performance reflects steady progress across all markets, with particularly strong growth in India and its Innovative Medicines segment.

Financial Highlights

Sun Pharma's consolidated gross sales for Q1 reached ₹137,861.00 million, marking a 10.1% year-over-year growth. The company's adjusted net profit (excluding exceptional items) rose by 5.7% to ₹29,961.00 million. However, the reported net profit stood at ₹22,786.00 million, compared to ₹28,356.00 million in the same quarter of the previous year, primarily due to exceptional items.

Market Performance

India continues to be a strong growth driver for Sun Pharma, with formulation sales in the country increasing by 13.9% to ₹47,211.00 million. The company maintained its position as the market leader, increasing its market share from 8.0% to 8.3% in the Indian pharmaceutical market.

In the United States, formulation sales reached US$473.00 million, showing a modest growth of 1.4%. This segment accounted for 29.3% of Sun Pharma's total consolidated sales.

Innovative Medicines Segment

Sun Pharma's Global Innovative Medicines sales, previously known as the Specialty business, demonstrated impressive growth. This segment recorded sales of US$311.00 million in Q1, up 16.9% year-over-year, and now accounts for 19.3% of the company's total consolidated sales.

R&D and Pipeline

The company continued its focus on research and development, investing ₹9,029.00 million (6.5% of sales) in R&D during the quarter. Sun Pharma's innovative R&D pipeline includes six novel entities in the clinical stage, with several candidates progressing through various phases of development.

US Drug Pricing Pressure

Despite the strong overall performance, Sun Pharma faces challenges in the US market due to President Trump's recent letters to major pharmaceutical companies demanding lower drug prices. The company's shares initially fell by 6% before recovering slightly to close 4% lower, leading losses in the Nifty Pharma index.

Sun Pharma derives approximately 20% of its revenues from innovative drugs sold in the US. While the company had not received direct communication regarding pricing as of their last quarterly conference call, the broader industry pressure could potentially impact future performance in the US market.

Management Commentary

Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, commented on the results: "Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to our performance. The U.S. launch of LEQSELVI represents an important step forward, offering a new treatment option for patients with severe alopecia areata. LEQSELVI augments our portfolio in dermatology and adds a growth engine to our Innovative Medicines business."

Looking Ahead

While Sun Pharma faces potential challenges in the US market due to drug pricing pressures, its strong performance in India and the growing Innovative Medicines segment provide a buffer against these headwinds. The company's continued focus on R&D and its robust pipeline of novel drugs position it well for future growth in the global pharmaceutical market.

Investors and analysts will be closely watching how Sun Pharma navigates the evolving regulatory landscape in the US while maintaining its growth trajectory in other key markets.

Sun Pharmaceutical Industries Limited , India's largest pharmaceutical company, has reported robust financial results for the first quarter of fiscal year 2026, demonstrating steady progress across all markets and significant growth in its Innovative Medicines business.

Financial Highlights

Sun Pharma's gross sales for Q1 FY26 reached ₹137,861.00 million, marking a 10.1% increase year-over-year. The company's adjusted net profit rose by 5.7% to ₹29,961.00 million, excluding exceptional items. However, the reported net profit stood at ₹22,786.00 million, compared to ₹28,356.00 million in Q1 FY25, due to certain exceptional charges.

Market Performance

India Formulations

Sun Pharma continued to strengthen its leadership position in the Indian pharmaceutical market. Sales in India grew by 13.9% to ₹47,211.00 million, accounting for 34.2% of total consolidated sales. The company's market share increased from 8.0% to 8.3%, maintaining its No. 1 ranking. Sun Pharma launched 5 new products in the Indian market during the quarter.

US Formulations

US formulation sales reached $473.00 million, representing a 1.4% growth and contributing 29.3% to total consolidated sales.

Global Innovative Medicines

The company's Global Innovative Medicines business, previously known as Specialty business, showed impressive growth of 16.9%, reaching $311.00 million. This segment now accounts for 19.3% of Q1 FY26 sales, highlighting Sun Pharma's successful expansion into innovative drug development.

Emerging Markets and Rest of World

Emerging Markets formulation sales grew by 5.1% to $298.00 million, while Rest of World markets saw a significant increase of 15.5%, reaching $219.00 million.

R&D and Product Pipeline

Sun Pharma continued its focus on research and development, investing ₹9,029.00 million (6.5% of sales) in R&D during Q1 FY26. The company's innovative R&D pipeline includes six novel entities in clinical stages. In the US market, Sun Pharma has 542 approved ANDAs and 119 pending approvals, along with 57 approved NDAs and 13 pending approvals.

Launch of Leqselvi in the US

A significant milestone for Sun Pharma this quarter was the US launch of Leqselvi, a JAK inhibitor for severe alopecia areata. This launch not only expands the company's dermatology portfolio but also adds a new growth engine to its Innovative Medicines business.

Leadership Transition

Sun Pharma announced an important leadership change during its 33rd Annual General Meeting. Dilip Shanghvi, the company's founder, will transition from his role as Managing Director. Kirti Ganorkar, a long-standing member of Sun Pharma's leadership team, will take over as the new Managing Director, subject to shareholder approval.

Outlook

Dilip Shanghvi, Chairman and Managing Director, commented on the results: "Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to our performance."

Looking ahead, Sun Pharma expects mid to high single-digit topline growth for FY26, with continued growth trajectory in its Global Specialty business. The company plans to maintain its R&D spend in the range of 6-8% of sales, with an increased focus on Specialty products.

As Sun Pharmaceutical Industries Limited continues to expand its global footprint and innovative product portfolio, it remains committed to delivering long-term value and touching more lives globally.